Panel Paper:
U.S. Health Care Industry Consolidation: Remedies Beyond Antitrust
*Names in bold indicate Presenter
Moreover, health care consolidation is a phenomenon with few policy solutions – although the Federal Trade Commission and Department of Justice occasionally review the few mergers and acquisitions that trigger its monetary threshold for regulatory oversight, they do not have the capacity to review every deal, and are often not successful when they challenge health care industry mergers in court. Furthermore, once consolidation occurs, it is nearly impossible to reverse. The present study considers policy levers that can be used to mitigate the negative impacts of health care consolidation.
In the course of conducting a case study on health care consolidation in Pittsburgh, I conducted semi-structured interviews with 20 community stakeholders to learn about how the consolidation in Pittsburgh has affected them, their employees, and the people they serve in the region. In addition to their insights on what the impacts of consolidation on the region have been, they have discussed ways in which they have attempted to cope with the negative impacts of consolidation or proposed potential ways to do so. These ideas go beyond Federal antitrust enforcement, and include policy actions that can occur at the state, county, and city level, as well as activities by non-governmental actors. Based on analysis of these interviews and a literature review of additional policy levers used to mitigate negative effects of other monopolistic businesses or industry examples, I present a set of policy proposals beyond antitrust that address the negative outcomes of health care consolidation.